Immix Biopharma, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
IMMX Nasdaq 2836 www.immixbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Immix Biopharma, Inc.

Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - Dec 9th, 2025 3:45 pm
Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - Dec 7th, 2025 4:20 pm
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis - Dec 7th, 2025 4:15 pm
We Think Immix Biopharma (NASDAQ:IMMX) Needs To Drive Business Growth Carefully - Nov 24th, 2025 4:21 am
Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch - Nov 12th, 2025 6:45 am
Immix Biopharma’s NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025 - Nov 3rd, 2025 6:45 am
Immix Biopharma, Inc. (NASDAQ:IMMX) surges 10%; individual investors who own 56% shares profited along with insiders - Oct 28th, 2025 4:01 am
Immix Biopharma to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference - Oct 14th, 2025 6:45 am
Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting - Oct 6th, 2025 2:05 pm
Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference - Oct 1st, 2025 6:45 am
Immix Biopharma Announces 50% Enrollment Milestone Surpassed in its ongoing relapsed/refractory AL Amyloidosis Clinical Trial, NEXICART-2 - Sep 18th, 2025 11:30 am
Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors - Sep 11th, 2025 7:15 am
Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang - Sep 8th, 2025 2:05 pm
Discover Immix Biopharma And 2 Other Promising Penny Stocks - Sep 4th, 2025 12:05 pm
Immix Biopharma to Present at the Stifel 2025 Healthcare Conference - Aug 25th, 2025 7:30 am
Immix Biopharma Loses US$9.2m Market Value But Insiders See Windfall Of US$19k - Aug 8th, 2025 7:27 am
Immix Biopharma Announces Other Serious Diseases Strategy - Aug 6th, 2025 10:30 am
Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion - Jul 11th, 2025 7:36 am
Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis - Jul 7th, 2025 7:35 am
Immix Biopharma (IMMX) Upgraded to Buy: What Does It Mean for the Stock? - Jun 6th, 2025 10:00 am